Full-Time

Head of Regulatory

Ambulatory Monitoring & Diagnostics

Philips

Philips

Healthcare technology for diagnosis, care, wellness

Compensation Overview

$171k - $291k/yr

No H1B Sponsorship

Cambridge, MA, USA + 2 more

More locations: Malvern, PA, USA | Chicago, IL, USA

Hybrid

Office-based role requiring at least three days in person per week. Must reside in or within commuting distance of a posted location; relocation benefits are not provided.

Bachelor's, Master's

Category
Legal & Compliance (1)
Requirements
  • At least 8 years of Regulatory Affairs experience with a bachelor's degree, or at least 6 years with a master's degree, in the medical device industry.
  • People leader experience.
  • Strong knowledge of relevant regulations and standards, including ISO 13485 and ISO 14971.
  • Ability to represent a medical device company with competent authorities during audits and prepare responses.
  • Experience with both new product development and sustaining activities.
  • Ability to meet the minimum physical, cognitive, and environmental job requirements with or without accommodation.
  • Ability to communicate effectively and influence cross-functional stakeholders using clinical expertise and knowledge of standard of care and medical device standards.
  • Willingness and ability to travel up to 15% as required by business needs.
  • US work authorization is required; candidates requiring sponsorship for a work-authorized visa now or in the future will not be considered.
  • Must reside in or within commuting distance of a posted location.
Responsibilities
  • Establish and execute the global regulatory strategy by aligning regulatory, legislative, and competitive landscape insights with product and commercial objectives.
  • Advise senior leadership on regulatory risks, opportunities, and market access decisions.
  • Lead and develop the global Regulatory Affairs organization through direction, talent development, succession planning, performance management, and functional leadership.
  • Drive regulatory compliance and market access across the product lifecycle.
  • Oversee global product registrations, approvals, CE Marking, clinical evaluations, regulatory submissions, and change management activities.
  • Represent the company to regulatory authorities, industry organizations, and external stakeholders.
  • Build relationships, influence regulatory policy discussions, negotiate approvals, and communicate regulatory developments across the organization.
  • Partner cross-functionally to integrate regulatory requirements into product development and business processes.
  • Lead regulatory planning, risk assessments, and compliance strategies.
  • Drive continuous improvement initiatives that enhance operational efficiency, quality, and regulatory outcomes.
Desired Qualifications
  • Experience authoring Class 2 510(k) submissions in cardiology.
  • A bachelor's or master's degree in Biomedical Engineering, Business Administration, Health Sciences, Pharmaceutical, Law, or an equivalent field.
  • Regulatory Affairs Regulatory Affairs Certification (RAC).

Philips develops health technology across professional medical devices, connected care, and consumer health products. Its offerings include diagnostic imaging and image-guided therapy, patient monitoring and clinical informatics, and everyday wellness products like oral and personal care. The company increasingly delivers integrated solutions through a Healthcare-as-a-Service subscription model and long-term partnerships with hospitals and health systems. Its aim is to improve people’s health and well-being by making advanced health technology easier to access and integrate into care.

Company Size

N/A

Company Stage

IPO

Headquarters

Andover, Minnesota

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • May 18, 2026 Stockholm selected Philips for hospital-at-home coverage across up to 15,000 patients annually.
  • Q1 2026 sales grew 4%, and Philips reiterated 2026 guidance on May 13, 2026.
  • 2025 free cash flow reached EUR 512 million, supporting investment and shareholder returns.

What critics are saying

  • August 2026 MDL still holds 624 Philips CPAP cases, extending legal drag.
  • January 19, 2026 settlement covers economics only; DOJ consent-decree talks still threaten Respironics.
  • A Respironics compliance failure can block U.S. sleep-device sales and tarnish Philips brand.

What makes Philips unique

  • June 4, 2026 WellSpan alliance makes Philips preferred vendor across CT, MR, X-ray, ultrasound, image-guided therapy.
  • August 6, 2026 ecosystem partnerships connect Philips monitoring from hospital beds to homes.
  • Philips combines diagnosis, connected care, and personal health across 64,317 employees at Q1 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.